Library - Page 8 - Scientific articles and publications about the drug Mexidol®.

Registered on ClinicalTrials

Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)

The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

The value of mitochondrial dysfunction in stabilization

The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)

The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

The value of mitochondrial dysfunction in stabilization

Neurological manifestations of post -shoe syndrome

Authors:

P.R. KAMCHATNOV¹, R.A. CHEREMIN², L.A. SKIPETROVA², A.V. CHUGUNOV¹

¹Federal State Budgetary Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russia;
²State Budgetary Healthcare Institution “Speech Pathology and Neurorehabilitation Center of the Moscow Department of Health”, Moscow, Russia.

Frequent neurological symptoms of Long-Covid and their correction paths

Author

Ostroumova T.M. - Ph.D., assistant department of the department of nervous diseases and neurosurgery of the Institute of Clinical Medicine named after N.V. Sklifosovsky FGAOU in the First MGMU named after THEM. Sechenova of the Ministry of Health of Russia (Sechenov University)

Place of publication:

03.2022

The use of Mexidol in patients with chemical and covid-19

Author:
A.I. FEDIN

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Asthenia and cognitive disorders against the background of the transformed infections of the Covid-19: possible correction routes

Author:
OSTROUMOVA T.M.

FGAOU in "First Moscow State Medical University named after THEM. Sechenov "Ministry of Health of Russia (Sechenov University), Moscow, Russia

The possibilities of increasing the effectiveness of patients with chronic brain ischemia against the background of Covid-19

Authors:
V.V. KOVALCHUK, I.I. ERSHOVA, N.V. MOLODOVSKAYA

St. Petersburg GBUZ "City Hospital No. 38 named after N.A. Semashko ", St. Petersburg, Russia

The role of antioxidant therapy in patients with the new coronavirus infection of the Covid-19 of the Motenza and Severe

Authors:
E.K. SHAVAROVA^1,2, E.R. KAZAKHMEDOV¹, M.V. ALEXEEVA¹, L.G. EZHOVA², Zh.D. KOBALAVA¹

¹Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation;
²Vinogradov City Clinical Hospital, Moscow Department of Health, Moscow, Russian Federation

The role of free-radical oxidation, hypoxia and their correction in the pathogenesis of Covid-19

Author:
A.V. SHCHULKIN, A.A. FILIMONOVA

FGBOU in the Ryazan State Medical University named after Acad. I.P. Pavlova "of the Ministry of Health of Russia

Antioxidants/Antihyxants-the missing puzzle of effective pathogenetic therapy of patients with Covid-19

Author:
T.A. VORONINA

Research Institute of Pharmacology. V.V. Zakusova, Moscow, Russian Federation

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

Registered on ClinicalTrials

L.V. STAKHOVSKAYA¹, N.A. SHAMALOV¹, D.R. KHASANOVA², E.V. MELNIKOVA³, A.S. AGAFINA⁴, K.V. GOLIKOV⁵, E.I. BOGDANOV⁶, A.A. YAKUPOVA⁶, L.V. ROSHKOVSKA⁷, L.V. LUKINYKH⁸, T.M. LOKSHTANOVA⁹, I.E. Poverennova¹⁰, L.A. SCHEPANKEVICH¹¹

¹Research Institute of Cerebrovascular Pathology and Stroke, N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
²Interregional Clinical and Diagnostic Center, Kazan, Russia;
³St. Petersburg City Hospital No. 26, St. Petersburg, Russia;
⁴St. Petersburg City Hospital No. 40 of the Kurortny Administrative District, St. Petersburg, Russia;
⁵St. Petersburg City Multidisciplinary Hospital No. 2, St. Petersburg, Russia;
⁶Kazan State Medical University, Kazan, Russia;
⁷St. Petersburg Nikolaevskaya Hospital, St. Petersburg, Russia;
⁸Vsevolozhsk Clinical Interdistrict Hospital, Leningrad Region, Russia.
⁹MUBZ City Clinical Hospital No. 1 named after N.I. Pirogov, Samara, Russia;
¹⁰State Budgetary Healthcare Institution Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
¹¹Federal State Budgetary Scientific Institution Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2017, No. 3, ISSUE 2

Cognitive disorders in patients with arterial hypertension

Authors:
V.V. ZAKHAROV^,P.A. CHERNOUSOV^,, K.A. VEKHOVA¹A.N. BOGOLEPOVA³¹I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
²N.I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia;
³Federal Center for Brain and Neurotechnology, Federal Medical and Biological Agency of Russia, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2024, Vol. 124, No. 4, Issue 2

Neurometabolic therapy of moderate cognitive disorders in patients with chronic brain ischemia

Authors:
E.A. ANTIPENKO¹, A.V. SHULYNDIN², K.M. BELYAKOV³

¹Federal State Budgetary Educational Institution of Higher Education, Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation, Nizhny Novgorod, Russia;
²Vectorpharm LLC, Moscow, Russia;
³Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod, Russia

Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol

Authors:
Z. A. GONCHAROVA, I. V. CHERNIKOVA, V. A. NAZAROVA, V. V. TOLMACHEVA, K. G. OVSEPYAN
Rostov State Medical University of the Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis

Author:
V.V. ZAKHAROV, N.V. VAKHNINA
Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov” of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis

Authors:
I.A. VOZNYUK^1,2, S.V. KOLOMETSEV^2,3, E.M. MOROZOVA¹

Arterial hypertension and cognitive disorders. The gaze of a neurologist

Author:
A.I. FEDIN

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Approaches to pharmacotherapy of vascular moderate cognitive disorders in patients of various age groups

Authors:
V.V. ZAKHAROV¹, A.I. FEDIN², E.A. MKHITARYAN^2,³

« 1 … 6 7 8 9 10 … 14 »